fruquintinib
hutchmed
['colorectal', 'fresco-2', 'rectal', 'fruquintinib']
results from the fresco-2 study led by our dr. arvind dasari support the meaningful survival improvement and manageable safety profile of fruquintinib in patients with refractory metastatic colorectal cancer: #esmo22 #endcancer
MD Anderson is a global leader in cancer care, research, education and training, and prevention. Appointments available: 1-877-632-6789